The short answer
BPC-157 and TB-500 get lumped together because both sit in the “recovery peptide” bucket — but they are different molecules with different mechanisms. The cleanest way to hold the distinction in your head: BPC-157 builds the local environment for repair; TB-500 helps cells move to where repair is needed. One is local, one is systemic.
Side-by-side comparison
| Property | BPC-157 | TB-500 |
|---|---|---|
| Class | Pentadecapeptide (15 amino acids) | Synthetic fragment of Thymosin Beta-4 |
| Origin | Derived from a human gastric-juice protein | Built around the actin-binding region of Tβ4 |
| Primary mechanism | Angiogenesis via the VEGF pathway; cytoprotection | Actin sequestration; promotes cell migration |
| Reach | Predominantly local, acts strongly at the site | Systemic, distributes broadly |
| Most-studied tissues | Tendon, gut, ligament (large preclinical record) | Wound, cardiac, corneal (reached human Tβ4 trials) |
| Human clinical data | Limited; mostly animal/cell-culture | Specific Tβ4 formulations (e.g. RGN-259) in human trials |
| Reconstitution | Bacteriostatic water; 10 mg in 2 mL = 5 mg/mL | Bacteriostatic water; 10 mg in 2 mL = 5 mg/mL |
| Research dose range | ~1–10 µg/kg/day (animal models) | ~2–10 µg/kg/dose, a few times/week (animal models) |
BPC-157: local cytoprotection and angiogenesis
BPC-157 is a stable pentadecapeptide derived from a protein found in gastric juice. Its defining research activity is promoting angiogenesis — the growth of new blood vessels — largely through the VEGF pathway, alongside broad cytoprotective effects. Because it is remarkably stable in the acidic gut, much of its literature centres on gastrointestinal and tendon models, where it acts strongly at the local site. The full mechanism and evidence base are in the BPC-157 research guide.
TB-500: systemic actin regulation and cell migration
TB-500 reproduces the active region of Thymosin Beta-4, a protein present in nearly every human cell. It binds monomeric actin and influences how the cytoskeleton assembles — which in turn governs how readily cells migrate toward an injury. It acts systemically rather than locally, and unlike BPC-157 it has the advantage that the underlying Thymosin Beta-4 biology has reached human clinical trials in specific formulations. The detail is in the TB-500 research guide.
Why they are studied together
Because the mechanisms are complementary — systemic migration (TB-500) plus local vascular support (BPC-157) — the two are one of the most documented pairings in regeneration research, informally called the “Wolverine protocol.” If your question is about combining them rather than choosing between them, the Wolverine protocol guide covers the stacking rationale and reconstitution.